A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

Phase 3 Completed 142 enrolled Tarsier Pharma

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy and safety of TRS01 eye drops compared to active comparator in subjects with active non-infectious anterior uveitis with or without uveitic glaucoma

Timeline

Start: 2021-09-20
Primary completion: 2023-06-29
Completion: 2023-06-29

Outcome

Missed primary endpoint

paper TRS01 was found to be inferior to topical steroids to control ACC PMID 41485727 ↗

release “today announced results from the noninfectious anterior uveitis TRS4VISION Trial. While the primary endpoint was not met” tarsierpharma.com ↗

Publications

Results Chu DS, Tsui E, Rifkin LM, Palestine AG, Rich C, Thorne JE, Haim-Langford D, Milman Z, Fulcher E, Neumann R, DE Smet MD; TRS4Vision Study Group. Dazdotuftide: Novel Treatment for Noninfectious Uveitis with Superior Intraocular Pressure Safety Profile: A Randomized Clinical Trial. Am J Ophthalmol. 2026 Apr;284:78-87. doi: 10.1016/j.ajo.2025.12.034. Epub 2026 Jan 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Prednisolone	Other / unclassified	1 %	Topical
Subject	dazdotuftide	Small molecule	1 %	Topical